CI

At a glance

ClinicalIndex Comparison Record
Phase 4Completed· 347 enrolled
Drug / intervention
mRNA COVID-19 Vaccine +1 morebiological
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT06038617
NCT06038617Phase 4Completed

A Prospective, Randomized, Open-label Clinical Trial to Assess the Safety of Simultaneous Vaccination With mRNA COVID-19 Vaccine and Other Vaccines in Young Children Aged 6 Months to <5 Years.

Duke University·interventional·Posted Sep 15, 2023·Updated May 13, 2026

In Brief

A Phase 4 clinical trial evaluating mRNA COVID-19 Vaccine and Routine Childhood Vaccinations for Fever After Vaccination and 2 related conditions. Completed, enrolled 347 participants across 5 sites.

Detailed Summary

This is a prospective, randomized, open-label clinical trial to evaluate the safety of COVID-19 vaccination and other routine childhood vaccines given simultaneously at Visit 1, as compared to sequential vaccination of COVID-19 vaccine and other vaccines at separate visits (Visits 1 and 2). Parent(s) or legal authorized representative(s) (LAR) will assess fever and other solicited systemic adverse events on the day of vaccination (Day 1) and the next 6 days (through Day 7) following Visit 1 and Visit 2 using either a web-based data collection system or a paper memory aid. Serious adverse events and adverse events of special interest will be captured during the entire study period. Parental/LAR perceptions about their child's vaccine schedule will be assessed on Day 7 following Visit 2.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
CountriesUnited States

Timeline

Phase 4CompletedFinished
202420252026
First PostedSep 15, 2023
Enrollment StartOct 30, 2023
Primary CompletionApr 24, 2025
Study CompletionJul 25, 2025
TodayJul 2, 2026
Enrollment to primary: 1.5 yearsPosted 2.8 years ago

Interventions

mRNA COVID-19 Vaccinebiological

ACIP Recommended Vaccine

Routine Childhood Vaccinationsbiological

ACIP Recommended Vaccines